Cherenkov imaging incorporating 3D surface imaging for TSET

用于TSET的结合表面成像的切伦科夫成像 摘要 全身皮肤电子放射治疗已被临床证明是有效的治疗真菌病 蕈样肉芽肿然而，由于设置定位的不确定性和患者在手术过程中的潜在移动， 全皮肤电子治疗（TSET），输送到患者皮肤组织的剂量可能偏离剂量 处方.切伦科夫发射从组织最近已被证明，提供了一个映射 与皮肤组织的辐射传递有关。信号最佳地被时间门控增强的 相机，同步到线性加速器脉冲，允许拒绝大多数背景 室内照明，并提供高剂量率的每次放射治疗的真实的时间视频。的 切伦科夫成像的实现提供了一种极好的技术，以检测异常， 治疗，否则会被忽视。该提案旨在推动这项技术， 通过临床试验监测TSET患者日常治疗交付的验证工具， 开发可应用于采集信号的适当校正，以确保其定量 准确记录皮肤剂量。三个最主要的因素，这改变了 剂量和切伦科夫信号之间的线性，是对透视方向、组织 曲率和组织光学特性。这些重要的修正是量化的这项试点研究， TSET与DoseOptics LLC合作，该公司开发了切伦科夫成像 辐射验证技术，完善辐射输送日常监测技术。我们 将通过比较在9 ℃下的体内测量值来比较切伦科夫成像的剂量测定准确性 使用OSLD和闪烁探测器定位。此外，我们还将进行光学测量， TSE治疗条件下已知组织光学特性的幻象和蒙特-卡罗模拟 对三个校正因子进行量化研究。我们还将开发覆盖皮肤剂量的技术 基于表面3D，从校正的切伦科夫图像到患者特定表面解剖结构获得 TSE治疗前获得的身体轮廓数据，以评估每日的实际皮肤剂量分布 TSE治疗和基于MC的剂量分布进行全面比较 治疗计划系统总的来说，这个项目将在最引人注目的系统上取得进展 用于放射治疗成像。该项目的核心是结合技术系统，测试 TSET设置中的实用程序。

Cherenkov imaging incorporating surface imaging for TSET Abstract Whole-body skin electron radiotherapy has been clinically demonstrated to be effective to treat mycosis fungoides. However, due to setup positioning uncertainties and potential patient movements during total skin electron therapy (TSET), dose delivered to the patient skin tissue can deviate from dose prescription. Cherenkov emission from tissue has recently been demonstrated, providing a mapping related to the radiation delivery to skin tissue. The signal is optimally captured by time-gated intensified cameras, synchronized to the linear accelerator pulses, allowing rejection of the majority of background room light, and providing real time video of each radiotherapy treatment with high dose rates. The implementation of Cherenkov imaging offers an excellent technology to detect abnormalities in the treatment, which would otherwise go unnoticed. This proposal seeks to advance this technology as a verification tool through a clinical trial to monitor the daily treatment delivery of TSET patients and develop proper corrections that can be applied to the acquired signal to ensure it is quantitatively accurate in documenting delivered skin dose. Three of the most dominant factors, which alter the linearity between dose and Cherenkov signal, are the corrections for perspective direction, tissue curvature, and tissue optical properties. These important corrections are quantified in this pilot study of TSET, in partnership with DoseOptics LLC, the company that developed the Cherenkov imaging technology for radiation verification, to perfect technology for daily monitoring of radiation delivery. We will compare the dosimetry accuracy of Cherenkov imaging by comparing measurements in-vivo at 9 locations using OSLD and Scintillator detectors. In addition, we will perform measurements in optical phantoms of known tissue optical properties at TSE treatment conditions and Monte-Carlo simulation studies to quantity the three correction factors. We will also develop techniques to overlay skin dose obtained from corrected Cherenkov image to patient-specific surface anatomy based on surface 3D body contour data obtained before TSE treatment to assess the actual skin dose distribution for daily TSE treatment and perform a comprehensive comparison of dose distribution based on MC-based treatment planning system. Taking together, this project will advance on the most compelling systems for radiotherapy imaging in decades. The core of the project is combined technology systems, testing the utility in the setting of TSET.